ReviewRMD open2024

Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases.

Martin Aringer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.